{"title":"T 细胞成功抗击癌症","authors":"E. Inderberg, S. Wälchli","doi":"10.56367/oag-043-11536","DOIUrl":null,"url":null,"abstract":"\n \n Else Marit Inderberg and Sébastien Wälchli from Oslo University Hospital explore what we need to know about T cells successfully fighting cancer. Cell-based immunotherapy uses the patient’s own immune cells to target and kill cancer cells in a specific manner. Lymphocytes called T cells are mainly used for this type of therapy, and to target them more efficiently against cancer cells, they are genetically modified to express chimeric antigen receptors (CAR) or T cell receptors (TCR) that bind proteins or peptides presented on the surface of cancer cells. There are currently six CAR T cell therapies approved for the treatment of blood cancers. However, none of these cellular therapies are yet available outside clinical studies for solid cancers.\n","PeriodicalId":475859,"journal":{"name":"Open Access Government","volume":"12 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"T cells successfully fighting cancer\",\"authors\":\"E. Inderberg, S. Wälchli\",\"doi\":\"10.56367/oag-043-11536\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n Else Marit Inderberg and Sébastien Wälchli from Oslo University Hospital explore what we need to know about T cells successfully fighting cancer. Cell-based immunotherapy uses the patient’s own immune cells to target and kill cancer cells in a specific manner. Lymphocytes called T cells are mainly used for this type of therapy, and to target them more efficiently against cancer cells, they are genetically modified to express chimeric antigen receptors (CAR) or T cell receptors (TCR) that bind proteins or peptides presented on the surface of cancer cells. There are currently six CAR T cell therapies approved for the treatment of blood cancers. However, none of these cellular therapies are yet available outside clinical studies for solid cancers.\\n\",\"PeriodicalId\":475859,\"journal\":{\"name\":\"Open Access Government\",\"volume\":\"12 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Access Government\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.56367/oag-043-11536\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Government","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.56367/oag-043-11536","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
奥斯陆大学医院的 Else Marit Inderberg 和 Sébastien Wälchli 探讨了我们需要了解的有关 T 细胞成功抗癌的知识。细胞免疫疗法利用患者自身的免疫细胞,以特定的方式靶向杀死癌细胞。为了更有效地针对癌细胞,T细胞经过基因改造,表达嵌合抗原受体(CAR)或T细胞受体(TCR),与癌细胞表面的蛋白质或肽结合。目前有六种 CAR T 细胞疗法获准用于治疗血癌。不过,这些细胞疗法还没有用于实体瘤的临床研究。
Else Marit Inderberg and Sébastien Wälchli from Oslo University Hospital explore what we need to know about T cells successfully fighting cancer. Cell-based immunotherapy uses the patient’s own immune cells to target and kill cancer cells in a specific manner. Lymphocytes called T cells are mainly used for this type of therapy, and to target them more efficiently against cancer cells, they are genetically modified to express chimeric antigen receptors (CAR) or T cell receptors (TCR) that bind proteins or peptides presented on the surface of cancer cells. There are currently six CAR T cell therapies approved for the treatment of blood cancers. However, none of these cellular therapies are yet available outside clinical studies for solid cancers.